The AJMC® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.
December 25th 2023
Our most-read content that featured lung cancer included articles on non–small cell lung cancer, how navigation programs can increase screening rates, and a potential link between antidepressants and lung cancer risk.
December 14th 2023
ACS Cancer Statistics Report Shows Record Drop in Cancer Mortality, But Persistent Disparities
January 13th 2021The 2021 American Cancer Society annual Cancer Statistics report found that the overall rate of cancer mortality continuously declined from 1991 to 2018 but also highlighted racial and geographic disparities.
Read More
Joanna Thompson Discusses What Makes a Patient High Risk for Lung Cancer
December 31st 2020There are several risk factors to review when determining whether or not a patient is high risk for lung cancer and should be screened, said Joanna Thompson, multidisciplinary program manager, Highlands Oncology Group.
Watch
Joanna Thompson on Engaging With PCPs for a Successful Lung Cancer Screening Program
December 10th 2020Highlands Oncology Group has found the most success getting the word out about its lung cancer screening program by directly engaging with primary care physicians (PCPs), said Joanna Thompson of Highlands Oncology Group.
Watch
Janssen Seeks FDA Approval of Amivantamab for Metastatic NSCLC With EGFR Exon 20 Insertion Mutations
December 4th 2020Data from the Phase I CHRYSALIS trial also support an expanded access program that makes some patients eligible for amivantamab treatment while the FDA reviews the submission.
Read More
Joanna Thompson Outlines How Highlands Oncology Group Screens for Lung Cancer
November 22nd 2020The Highlands Oncology Group partners with primary care providers to identify patients at high risk of lung cancer so the specialists can do a more in-depth screening, explained Joanna Thompson, multidisciplinary program manager, Highlands Oncology Group.
Watch
Libtayo Accepted for FDA Priority Review in NSCLC With PD-L1 Expression
November 3rd 2020Regeneron’s PD-1 inhibitor Libtayo was accepted for priority FDA review for the treatment of first-line locally advanced or metastatic non–small cell lung cancer (NSCLC) with PD-L1 expression of at least 50%.
Read More
KRAS G12C Inhibitor Shows Promising Effects in NSCLC, Other Solid Tumors
October 29th 2020A pair of abstracts based on a phase 1/2 trial of adagrasib (MRTX849) a KRAS G12C inhibitor, showed promising results for patients with lung, bowel, and other solid tumors, researchers reported at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
Read More
Dr Blythe Adamson: PD-L1 as a Predictive Biomarker in Lung Cancer Continues to Evolve
October 6th 2020Personalized recommendations for patients with non–small cell lung cancer with squamous histology could benefit from research on treatment choice and biomarkers, noted Blythe Adamson, PhD, MPH, principal quantitative scientist at Flatiron Health.
Watch
Combo Treatment Bests Cemiplimab Monotherapy, Phase 2 Data Show
September 30th 2020Study results presented during the virtual European Society for Medical Oncology meeting demonstrated the superiority of cemiplimab (Libtayo) plus ipilimumab vs cemiplimab monotherapy for non–small cell lung cancer.
Read More